CALQUENCE six-year follow-up data reinforce long-term benefit in chronic lymphocytic leukemia, and data across multiple hematology assets showcase breadth of promising early pipeline
New,.
– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support
/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the upcoming presentation of five posters highlighting data from the Company s.
Riley was just a year and a half old when he was diagnosed with a rare genetic condition that affects about 1 in 200,000 people. With the specialized care and teamwork of the Center for Cell and Gene Therapy for Non-Malignant Conditions, Riley, now 5, is back home with his siblings and growing stronger every day.
Jocelyn was born with a rare primary immunodeficiency disorder that often meant she couldn’t participate in the same things as other kids her age. But that has changed with a new stem cell transplant approach at Johns Hopkins All Children’s that allowed her brother to be a half-matched donor.